UNSPSC 51284604: Imipenem

This classification denotes a beta-lactam antibiotic with the molecular formula C12H17N3O4S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71OTZ9ZE0A, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5r-(5-alpha,6-alpha(r*)))- but generally known as imipenem, which bears US NIH Compound Identifier 47317. European Medicines Agency schedules Imipenem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08151MIG.

UNSPSC 51284604 Imipenem is a Commodity code that reflects state and local procurement of specific pharmaceutical products, though recent solicitation activity under this code shows minimal direct alignment with imipenem itself. State and local health departments, county public health agencies, and special-purpose health districts are the primary issuing bodies using this code family. The actual purchasing under the code centers on critical pharmaceutical inventory — antimicrobials, emergency medications, and related controlled substances — acquired through competitive bidding processes often leveraged against established cooperative purchasing agreements or piggyback contracts with pharmaceutical distributors and specialty vendors.

Geographic activity is concentrated in the South and Midwest. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse cooperative to Chartwell Rx LLC on August 28, 2026 (Bid 26-482DPH-PREPD-B-53392, IFB notice type, closed award). Seminole County, Florida posted an IFB on June 30, 2026 (IFB60459723LAS, due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. Neither recent opportunity directly solicited imipenem; the code shows limited relevant recent activity aligned to its nominal scope, suggesting either sparse demand or systematic miscoding of related antimicrobial and critical-care pharmaceutical procurements at the state and local level.